High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma

Abstract The C-reactive protein-to-albumin ratio (CAR) has not been assessed in diffuse large B cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma). This retrospective study evaluated the prognostic value of CAR in 186 DLBCL patients. A CAR value of 0.158 was selected as the most discriminat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jongheon Jung, Hyewon Lee, Ja Yoon Heo, Myung Hee Chang, Eunyoung Lee, Weon Seo Park, Ju-Hyun Park, Hyeon-Seok Eom
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9dffc3475cc74dce869a7d65ac65ad6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9dffc3475cc74dce869a7d65ac65ad6b
record_format	dspace
spelling	oai:doaj.org-article:9dffc3475cc74dce869a7d65ac65ad6b2021-12-02T13:23:58ZHigh level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma10.1038/s41598-021-82087-62045-2322https://doaj.org/article/9dffc3475cc74dce869a7d65ac65ad6b2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82087-6https://doaj.org/toc/2045-2322Abstract The C-reactive protein-to-albumin ratio (CAR) has not been assessed in diffuse large B cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma). This retrospective study evaluated the prognostic value of CAR in 186 DLBCL patients. A CAR value of 0.158 was selected as the most discriminative cut-off for identifying patients with high CAR values (73/141 patients, 51.8%). During a median follow-up of 32.5 months, the high CAR group had significantly poorer complete response to induction therapy (64.4% vs. 92.6%; p < 0.001), 3-year overall survival (OS) (68.3% vs. 96.2%; p < 0.0001), and 3-year progression-free survival (PFS) (53.5% vs. 88.0%; p < 0.0001). After adjusting for the International Prognostic Index components, a high CAR value independently predicted poor OS (HR: 6.02, 95% CI 1.19–30.38; p = 0.030) and PFS (HR: 3.62, 95% CI 1.40–9.36; p = 0.008). In an independent validation cohort (n = 50), patients with CAR > 0.158 also showed worse 3-year OS (47.9% vs. 87.2%, p = 0.0035) and 3-year PFS (36.1% vs. 82.1%, p = 0.0011). A high CAR remained significantly associated with poor outcomes for > 60-year-old patients (OS: p = 0.0038, PFS: p = 0.0015) and younger patients (OS: p = 0.0041, PFS: p = 0.0044). Among older patients, a high CAR value also predicted non-relapse mortality (p = 0.035). Therefore, the CAR might complement the International Prognostic Index in DLBCL cases.Jongheon JungHyewon LeeJa Yoon HeoMyung Hee ChangEunyoung LeeWeon Seo ParkJu-Hyun ParkHyeon-Seok EomNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jongheon Jung Hyewon Lee Ja Yoon Heo Myung Hee Chang Eunyoung Lee Weon Seo Park Ju-Hyun Park Hyeon-Seok Eom High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma
description	Abstract The C-reactive protein-to-albumin ratio (CAR) has not been assessed in diffuse large B cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma). This retrospective study evaluated the prognostic value of CAR in 186 DLBCL patients. A CAR value of 0.158 was selected as the most discriminative cut-off for identifying patients with high CAR values (73/141 patients, 51.8%). During a median follow-up of 32.5 months, the high CAR group had significantly poorer complete response to induction therapy (64.4% vs. 92.6%; p < 0.001), 3-year overall survival (OS) (68.3% vs. 96.2%; p < 0.0001), and 3-year progression-free survival (PFS) (53.5% vs. 88.0%; p < 0.0001). After adjusting for the International Prognostic Index components, a high CAR value independently predicted poor OS (HR: 6.02, 95% CI 1.19–30.38; p = 0.030) and PFS (HR: 3.62, 95% CI 1.40–9.36; p = 0.008). In an independent validation cohort (n = 50), patients with CAR > 0.158 also showed worse 3-year OS (47.9% vs. 87.2%, p = 0.0035) and 3-year PFS (36.1% vs. 82.1%, p = 0.0011). A high CAR remained significantly associated with poor outcomes for > 60-year-old patients (OS: p = 0.0038, PFS: p = 0.0015) and younger patients (OS: p = 0.0041, PFS: p = 0.0044). Among older patients, a high CAR value also predicted non-relapse mortality (p = 0.035). Therefore, the CAR might complement the International Prognostic Index in DLBCL cases.
format	article
author	Jongheon Jung Hyewon Lee Ja Yoon Heo Myung Hee Chang Eunyoung Lee Weon Seo Park Ju-Hyun Park Hyeon-Seok Eom
author_facet	Jongheon Jung Hyewon Lee Ja Yoon Heo Myung Hee Chang Eunyoung Lee Weon Seo Park Ju-Hyun Park Hyeon-Seok Eom
author_sort	Jongheon Jung
title	High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma
title_short	High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma
title_full	High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma
title_fullStr	High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma
title_full_unstemmed	High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma
title_sort	high level of pre-treatment c-reactive protein to albumin ratio predicts inferior prognosis in diffuse large b-cell lymphoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9dffc3475cc74dce869a7d65ac65ad6b
work_keys_str_mv	AT jongheonjung highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma AT hyewonlee highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma AT jayoonheo highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma AT myungheechang highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma AT eunyounglee highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma AT weonseopark highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma AT juhyunpark highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma AT hyeonseokeom highlevelofpretreatmentcreactiveproteintoalbuminratiopredictsinferiorprognosisindiffuselargebcelllymphoma
_version_	1718393170611404800

High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma

Ejemplares similares